{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Promising Clinical Results for Cancer Associated With VHL Disease

Activity Steps

1 Activity
2 Take Test 3Certificate

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify features of von Hippel-Lindau disease (VHL) and belzutifan.
  2. Analyze results from the phase 2, open-label, single group trial of belzutifan for the treatment of patients with VHL.

Learning Outcomes

Seventy-five percent of health care practitioners will demonstrate knowledge of the use of belzutifan for the management of neoplasms associated with von Hippel-Lindau disease (VHL) by achieving a minimum score of 70% on the posttest.

Disclosures

The author(s), faculty, staff, and planners in any position to control the content of this activity, have disclosed that they have no fi nancial relationships with, or fi nancial interests in, any commercial companies relevant to this educational activity.

Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH
  • NM - BON 1.0 CH
  • SC - BON 1.0 CH
  • WV - BOERN 1.0 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.













Planner
Test Code: OT0322
Published: March 2022
Expires: 3/7/2025
Sources: Oncology Times
Required Passing Score: 8/10 (80%)
Authors: Kelly Wolfgang
Categories: Advanced Practice Nursing , Cancer , Oncology
Specialties: Advanced Practice Nursing, Oncology
Topics: von Hippel-Lindau disease